Alivus Life Sciences, formerly Glenmark Life Sciences Limited, delivered a strong financial performance in the second quarter of FY27, with net profit surging 51.3% year-on-year (YoY) and EBITDA margins touching a record 41.8%, driven by favourable product mix, new launches and operating efficiencies.

 

Revenue from operations rose 16% YoY to Rs 682 crore in Q2FY27, supported by broad-based growth across its non-GPL business, which expanded 20.8% during the quarter.

 

Profitability registered an even sharper improvement. EBITDA jumped 47% YoY to Rs 285.1 crore, with margins expanding 880 basis points year-on-year and 520 basis points sequentially to 41.8%.

 

Net profit (PAT) climbed 51.3% YoY to Rs 196.8 crore, while PAT margin improved 680 basis points year-on-year to 28.9%.

 

For the first half of FY27, revenue from operations grew 11.1% YoY to Rs 1,322.4 crore. EBITDA increased 38.4% to Rs 519.2 crore, with margins expanding 780 basis points to 39.3%. PAT rose 41.9% to Rs 356.9 crore, while PAT margins improved 590 basis points to 27%.

 

The company also reported robust cash generation, with free cash flow of Rs 270.2 crore. Cash and cash equivalents, including short-term investments, stood at Rs 1,011.6 crore as of September 30, 2026.

 

Commenting on the performance, Yasir Rawjee, MD & CEO, Alivus Life Sciences Limited, said, “Q2FY27 was another strong quarter for us, with revenue growing 16.0% YoY, supported by healthy demand across all key markets and robust contributions from recent launches. Non-GPL business momentum was maintained, while CDMO business saw a meaningful pick-up during the quarter.

 

"The improving business mix and greater operating efficiencies also translated into better underlying profitability. Looking ahead, our ongoing capacity expansion and healthy development pipeline give us confidence in sustaining this momentum and delivering consistent growth.”

 

Tushar Mistry, CFO, Alivus Life Sciences Limited, said, “We delivered a strong financial performance in Q2FY27, with healthy revenue growth, improved profitability and robust cash generation. Revenue grew 16.0% YoY, supported by a favourable product mix.

 

'Healthy operating performance translated into strong cash generation, with cash flow from operations of Rs. 270 crores during H1FY27. With cash and cash equivalents of Rs. 1,012 crores as of September 30, 2026, we have ample financial flexibility to support our growth initiatives while maintaining a healthy, debt-free balance sheet.

 

Going forward, we remain focused on sustaining profitable growth, maintaining financial discipline and creating long-term value.”

 

The results underscore Alivus Life Sciences' improving profitability, strong cash position and continued growth momentum, with capacity expansion, recent product launches and a healthy development pipeline expected to support its next phase of growth.